This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okuno, S. Articles by Tsujihara, K. Search for Related Content PubMed PubMed Citation Articles by Okuno, S. Articles by Tsujihara, K.

Complete Regression of Xenografted Human Carcinomas by Camptothecin Analogue-Carboxymethyl Dextran Conjugate (T-0128)

Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama 335-8505 [S. O., T. Y., S. Y., S. K., N. T., T. K., K. T.], and Discovery Research Laboratory, Osaka 532-8505, [M. H., Y. S., J. I.], Japan

Clinically available camptothecins (CPTs), such as irinotecan (CPT-11) and topotecan, represent one of the most promising classes of antitumor agents, despite their toxicity. To improve their pharmacological profiles, a new macromolecular prodrug, denoted T-0128, was synthesized. This prodrug is a novel CPT analogue (T-2513)-carboxymethyl (CM) dextran conjugate via a triglycine spacer, with a molecular weight of M_r 130,000. This study was designed to test the concept that the rational design of a CPT-polymer conjugate would increase the efficacy of the parent drug. The in vivo antitumor study against Walker-256 carcinoma demonstrated that T-0128 was 10 times as active as T-2513, supporting this concept. Additionally, comparative efficacy studies of T-0128, T-2513, CPT-11, and topotecan were performed using a panel of human tumor xenografts in nude mice, showing the advantage of T-0128 over these CPTs. The maximal tolerated doses (MTDs) of T-0128, T-2513, and CPT-11 were comparable. Even a single i.v. injection of T-0128 at 6 mg/kg (based on the amount of T-2513 bound to CM dextran) induced complete regression of MX-1 mammary carcinoma. T-0128 at 10 mg/kg weekly for 3 weeks (one-tenth of its MTD) cured LX-1 lung carcinoma. Also, T-0128 below its MTD consistently cured or regressed St-4 gastric and HT-29 colorectal tumor xenografts that are highly refractory to CPTs. These demonstrate the broad range of therapeutic doses achieved with T-0128. Pharmacokinetic studies were performed to correlate the efficacy results obtained for T-0128 with plasma and tissue drug concentrations using Walker-256 tumor-bearing rats. Results showed that after i.v. administration of T-0128, the conjugate continued to circulate at a high concentration for an extended period, resulting in tumor accumulation. In the tumor, the sustained release of T-2513 occurred. In contrast, T-2513 disappeared rapidly from the body. The significant increases in the amount and exposure time of released T-2513 in the tumor explain well the enhanced efficacy of T-0128. In conclusion, this study indicated that T-0128 improved the potency of T-2513, demonstrating the proof of the above concept.

This article has been cited by other articles:

				S. V. Govindan, T. M. Cardillo, S.-J. Moon, H. J. Hansen, and D. M. Goldenberg CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates Clin. Cancer Res., October 1, 2009; 15(19): 6052 - 6061. [Abstract] [Full Text] [PDF]

				S. A. Veltkamp, E. O. Witteveen, A. Capriati, A. Crea, F. Animati, M. Voogel-Fuchs, I. J.G.M. van den Heuvel, J. H. Beijnen, E. E. Voest, and J. H.M. Schellens Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors Clin. Cancer Res., November 15, 2008; 14(22): 7535 - 7544. [Abstract] [Full Text] [PDF]

				T. Schluep, J. Hwang, J. Cheng, J. D. Heidel, D. W. Bartlett, B. Hollister, and M. E. Davis Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models Clin. Cancer Res., March 1, 2006; 12(5): 1606 - 1614. [Abstract] [Full Text] [PDF]

				F. Fujita, M. Koike, M. Fujita, Y. Sakamoto, S. Okuno, T. Kawaguchi, S. Yano, T. Yano, S. Kiuchi, T. Fujiwara, et al. MEN4901/T-0128, a New Camptothecin Derivative-Carboxymethyldextran Conjugate, Has Potent Antitumor Activities in a Panel of Human Tumor Xenografts in Nude Mice Clin. Cancer Res., February 15, 2005; 11(4): 1650 - 1657. [Abstract] [Full Text] [PDF]

				Y. Tong, Q. Yang, C. Vater, L.K. Venkatesh, D. Custeau, T. Chittenden, G. Chinnadurai, and H. Gourdeau The Pro-apoptotic Protein, Bik, Exhibits Potent Antitumor Activity That Is Dependent on Its BH3 Domain Mol. Cancer Ther., December 1, 2001; 1(2): 95 - 102. [Abstract] [Full Text] [PDF]

				M. De Cesare, G. Pratesi, P. Perego, N. Carenini, S. Tinelli, L. Merlini, S. Penco, C. Pisano, F. Bucci, L. Vesci, et al. Potent Antitumor Activity and Improved Pharmacological Profile of ST1481, a Novel 7-substituted Camptothecin Cancer Res., October 1, 2001; 61(19): 7189 - 7195. [Abstract] [Full Text] [PDF]